Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1

Authors :: Eron J
Orkin C
Cunningham D
Pulido F
Post F
De Wit S
Lathouwers E
Hufkens V
Jezorwski J
Petrovic R
Brown K
Van Landuyt E
Opsomer M
EMERALD study group
Source :: ANTIVIRAL RESEARCH, r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA, instname
Publication Year :: 2019
Publisher :: ELSEVIER SCIENCE BV, 2019.

ISSN :: 01663542
Database :: OpenAIRE
Journal :: ANTIVIRAL RESEARCH, r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA, instname
Accession number :: edsair.RECOLECTA.....3f1237ae0ca6130da31226590e4ffc19

Tools